



Ocular Therapeutix™ to Present at the Piper Jaffray 27th Annual Healthcare Conference

November 24, 2015

BEDFORD, Mass.--(BUSINESS WIRE)--Nov. 24, 2015-- Ocular Therapeutix™, Inc.(NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.D., President, Chief Executive Officer and Chairman, will participate in a fireside chat presentation at the Piper Jaffray 27th Annual Healthcare Conference on Wednesday, December 2, 2015 at 9:30 a.m. ET at The New York Palace Hotel in New York City.

A live audio webcast of the presentation can be accessed through the Calendar of Events section of the Company's website at investors.ocutx.com. A replay of the webcast will be available on the Company's website for two weeks following the presentation.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead product candidate, DEXTENZA™, is in Phase 3 clinical development for post-surgical ocular inflammation and pain and allergic conjunctivitis, and in Phase 2 clinical development for inflammatory dry eye disease. An NDA for the post-operative ocular pain indication has been submitted to the FDA and a third Phase 3 clinical trial is being conducted for post-operative ocular inflammation and pain. The Company's product candidate, OTX-TP (sustained release travoprost) intracanalicular depot, has completed a Phase 2b clinical trial for glaucoma and ocular hypertension. Ocular Therapeutix is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20151124006084/en/>

Source: Ocular Therapeutix, Inc.

Investors

Ocular Therapeutix, Inc.

Brad Smith

Chief Financial Officer

bsmith@ocutx.com

or

Burns McClellan on behalf of Ocular Therapeutix

Kimberly Minarovich, 212-213-0006

kminarovich@burnsmc.com

or

Media

Ocular Therapeutix, Inc.

Scott Corning

Vice President of Sales and Marketing

scorning@ocutx.com